Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.

Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E.

Diabetes. 2008 Aug;57(8):2028-36. doi: 10.2337/db07-1623. Epub 2008 May 13.

2.

Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses.

Jayanthi S, Buie S, Moore S, Herning RI, Better W, Wilson NM, Contoreggi C, Cadet JL.

Mol Psychiatry. 2010 Jan;15(1):101-12. doi: 10.1038/mp.2008.50. Epub 2008 May 13.

3.

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

Ooi EM, Barrett PH, Chan DC, Watts GF.

Clin Sci (Lond). 2008 May;114(10):611-24. doi: 10.1042/CS20070308. Review.

PMID:
18399797
4.

Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

Jeong WI, Osei-Hyiaman D, Park O, Liu J, Bátkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G.

Cell Metab. 2008 Mar;7(3):227-35. doi: 10.1016/j.cmet.2007.12.007.

5.

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.

Herling AW, Kilp S, Elvert R, Haschke G, Kramer W.

Endocrinology. 2008 May;149(5):2557-66. doi: 10.1210/en.2007-1515. Epub 2008 Feb 14.

PMID:
18276749
6.

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A.

Gastroenterology. 2008 Feb;134(2):432-9. doi: 10.1053/j.gastro.2007.11.039. Epub 2007 Nov 28.

PMID:
18242211
7.

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A.

Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558.

PMID:
18022033
8.

High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.

Cannon CP.

Clin Cornerstone. 2007;8 Suppl 6:S14-23. Review.

PMID:
17948363
9.
10.

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.

Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Müller G, Schmoll D, Kramer W.

Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E826-32. Epub 2007 Jun 26.

11.

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.

Hepatology. 2007 Jul;46(1):122-9.

PMID:
17526015
12.

The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.

Serrano A, Del Arco I, Javier Pavón F, Macías M, Perez-Valero V, Rodríguez de Fonseca F.

Neuropharmacology. 2008 Jan;54(1):226-34. Epub 2007 Mar 24.

PMID:
17467748
13.

The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species.

Siegmund SV, Qian T, de Minicis S, Harvey-White J, Kunos G, Vinod KY, Hungund B, Schwabe RF.

FASEB J. 2007 Sep;21(11):2798-806. Epub 2007 Apr 17.

PMID:
17440119
14.

Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats.

Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y, Richard D.

Diabetes. 2006 Dec;55(12):3403-10.

15.

Critical role of STAT3 in leptin's metabolic actions.

Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L.

Cell Metab. 2006 Jul;4(1):49-60.

16.

Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity.

Uno K, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Imai J, Hasegawa Y, Gao J, Kaneko K, Iwasaki H, Ishihara H, Sasano H, Inukai K, Mizuguchi H, Asano T, Shiota M, Nakazato M, Oka Y.

Science. 2006 Jun 16;312(5780):1656-9.

17.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

PMID:
16478899
18.

MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance.

Jeon JY, Bradley RL, Kokkotou EG, Marino FE, Wang X, Pissios P, Maratos-Flier E.

Diabetes. 2006 Feb;55(2):428-34.

19.

Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.

Bermúdez-Siva FJ, Serrano A, Diaz-Molina FJ, Sánchez Vera I, Juan-Pico P, Nadal A, Fuentes E, Rodríguez de Fonseca F.

Eur J Pharmacol. 2006 Feb 15;531(1-3):282-4. Epub 2006 Jan 19.

PMID:
16423347
20.

Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit.

Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW.

Neuron. 2005 Dec 22;48(6):1055-66.

Supplemental Content

Support Center